Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COVID-19 Vaccine Candidate
- Development stage
- Unknown
- Lead developer
- Vaxart
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
This is an oral pill vaccine candidate developed by Vaxart for the prevention of COVID-19. It is currently undergoing a Phase 2b clinical trial, comparing its efficacy against an approved mRNA comparator. The development of this candidate is supported by a project award from the U.S. government's BARDA and NIAID, and Dynavax has licensed exclusive worldwide rights for its development and commercialization.
- Other names
- Vaxart's oral pill COVID-19 vaccine candidate
Beyond the preview
Go deeper on COVID-19 Vaccine Candidate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COVID-19 Vaccine Candidate.